Ashutosh Sureka

Paul Fehlner joins Spyre Therapeutics, Inc. as Chief IP Counsel with science and law expertise

Paul Fehlner joins Spyre Therapeutics, Inc. as Chief IP Counsel with science and law expertise
Spyre taps Paul Fehlner for IP

Spyre Therapeutics, Inc. has announced the appointment of Paul Fehlner as Chief IP Counsel, bringing more than thirty years of experience at the intersection of science and law.

Fehlner is tasked with safeguarding the company innovations and intellectual property strategy as Spyre Therapeutics, Inc. advances in its research and development efforts.

Spyre Therapeutics, Inc. was recently named a 2026 IncBestWorkplaces honoree for its collaborative workplace culture. The company is also pursuing advanced therapies for ulcerative colitis and Crohn’s disease. These developments come as Spyre expands its research and development initiatives.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.